From Wikipedia, the free encyclopedia
|Systematic (IUPAC) name|
|CAS Registry Number|
|Molecular mass||387.90 g/mol|
|(what is this?)|
Nemonapride (Emilace) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist. It has affinity for sigma receptors.
5-Chloro-2-methoxy-4-(methylamino)benzoic acid (1) is acylated with Ethyl chloroformate to give the mixed anhydride; Amidation then occurs in a second step via reaction with 3-amino-1-benzyl-2-methylpyrrolidine to give Nemonapride (2).
|This article does not cite any references or sources. (November 2009)|
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|